Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5570576 | 0.99 | CHRM3 (0.55) | CHRM3FAAHMGLLDRD2CYP2D6 | |
| SCHEMBL7037977 | 0.85 | CHRM3 (0.69) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL8294659 | 0.84 | CHRM3 (0.50) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL28744419 | 0.83 | CYP2D6 (0.73) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL5570472 | 0.83 | CHRM3 (0.49) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL4176561 | 0.82 | SLC6A4 (0.58) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL30799020 | 0.82 | SLC6A4 (0.58) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL12438436 | 0.82 | CYP2D6 (0.71) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL1512308 | 0.81 | CHRM3 (0.72) | CHRM3 | |
| SCHEMBL14389982 | 0.80 | SIGMAR1 (0.56) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | CHRM3 422/4885FAAH 464/4885MGLL 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.